MedCity News
SEPTEMBER 4, 2023
A new report predicted that generative AI tools will increasingly streamline many aspects of a clinician’s day in the next five to 10 years — and that this is particularly true for tools that can automate diagnoses and respond to patients’ questions.
European Pharmaceutical Review
SEPTEMBER 4, 2023
The National Institute for Health and Care Excellence (NICE) has recommended Chiesi’s Elfabrio ® (pegunigalsidase alfa) for Fabry disease (alpha-galactosidase deficiency) in adults. A new Fabry disease treatment The agreement made in the NICE’s Final Draft Guidance means there is now a “new treatment option for people living with Fabry disease across England,” according to Dr Kamran Iqbal, Head of Medical Affairs for Global Rare Diseases at Chiesi UK&I. “Fabry disease brings a mu
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
SEPTEMBER 4, 2023
Apprehension among practices and providers is understandable, given the complexity and variance of VBC contracts. However, instead of feeling overwhelmed and burdened by VBC, practices can slowly embrace these concepts by leveraging the many tools they already have in place or that exist in the healthcare ecosystem.
European Pharmaceutical Review
SEPTEMBER 4, 2023
According to the US Federal Trade Commission (FTC), Amgen is to be barred from leveraging its drug portfolio to disadvantage its industry competitors. The biopharma company will be required to seek prior approval before acquiring related products. The FTC has settled on a proposed consent order with Amgen Inc. to address the potential competitive harm Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc could bring.
MedCity News
SEPTEMBER 4, 2023
By following these foundational data best practices, healthcare organizations will harness the power of their data to provide superior patient care while safeguarding patient privacy and compliance.
European Pharmaceutical Review
SEPTEMBER 4, 2023
Included in Issue 4 of European Pharmaceutical Review : FOREWORD Dissolution testing – a dual role David Elder, David P Elder Consultancy REGULATORY INSIGHT EU packaging reform: a prescription for change? Maciej Adamczyk and Monika Pyzio-Michalik, DBS Law Firm EVENT PREVIEW Modern methods in microbiology and analytics PharmaLab Congress DRUG DELIVERY Dry powder delivery to the lungs Jnanadeva Bhat, ACG EVENT PREVIEW CPHI Barcelona 2023: what to expect Featuring company profiles from BioSpectra,
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
SEPTEMBER 4, 2023
iNtRON's contract is part of the US Army’s DEVCOM strategy to develop drugs to treat antibiotic-resistant UTIs.
MedCity News
SEPTEMBER 4, 2023
Increasingly, patients in the U.S. look to Canada for more affordable prescription options since the Canadian government regulates drug costs. Some companies have noticed and are beginning to capitalize on the demand.
PharmaTimes
SEPTEMBER 4, 2023
The therapy has been developed for the treatment of Fabry disease among adult patients - News - PharmaTimes
MedCity News
SEPTEMBER 4, 2023
After five years of enrolling in a Medicare Advantage plan, 48.3% of non-dually enrolled beneficiaries left their contract and 53.4% of dually enrolled beneficiaries did, a new study found.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaTimes
SEPTEMBER 4, 2023
The therapy has been developed for the treatment of migraine among adults - News - PharmaTimes
MedCity News
SEPTEMBER 4, 2023
Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2O Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.
Pharmaceutical Technology
SEPTEMBER 4, 2023
The Japanese MHLW has accepted GSK’s supplementary new drug application (sJNDA) for Nucala (mepolizumab) to treat chronic rhinosinusitis
Copyright Clearance Center
SEPTEMBER 4, 2023
CCC, a leader in advancing copyright, accelerating knowledge, and powering innovation, in partnership with the GO FAIR Foundation, will host its inaugural FAIR Forum on The Evolving Role of Data in the AI Era' on 18 September at Poortgebouw, the University of Leiden, the Netherlands.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmaTech
SEPTEMBER 4, 2023
This executive summary highlights strategies that can be used to maximize long-acting parenteral formulations using nanoparticles, microspheres and in-situ forming gels.
Copyright Clearance Center
SEPTEMBER 4, 2023
Writers in Hollywood are the latest to declare concerns that technology based in powerful artificial intelligence tools may jeopardize their livelihoods.
Pharmaceutical Technology
SEPTEMBER 4, 2023
The company published a study showing lyso-Gb1 (glucosylsphingosine) as a diagnostic and predictive biomarker for the rare metabolic disease.
PharmaTech
SEPTEMBER 4, 2023
Webinar Date/Time: Thursday, October 12, 2023 at 11am EDT | 4pm BST | 5pm CEST
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
SEPTEMBER 4, 2023
Bidco has signed an agreement to acquire British biopharmaceutical services company Ergomed in a deal valued at about GBP703.1m ($884.79m).
PharmaTech
SEPTEMBER 4, 2023
Webinar Date/Time: Wed, Oct 11, 2023 11:00 AM EDT
Pharmaceutical Technology
SEPTEMBER 4, 2023
Biocon Generics has purchased the US-based oral solid dosage manufacturing facility of Eywa Pharma for a total consideration of $7.7m.
Pharmaceutical Technology
SEPTEMBER 4, 2023
Amgen and Horizon Therapeutics have reached a consent order agreement with the FTC to resolve the ongoing administrative lawsuit.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
SEPTEMBER 4, 2023
Private Equity firm Permira has announced that it is taking the company private, following many other UK firms.
Pharmaceutical Technology
SEPTEMBER 4, 2023
The Biden Administration has released the anticipated list of ten drugs selected for Medicare price negotiations under the IRA.
Expert insights. Personalized for you.
125 
Let's personalize your content